Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'

October 12, 2026 9:34 AM EDT Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login